ONCT — Oncternal Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Brief: Oncternal Therapeutics Workforce Reduction Of About 10 Employees
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
Oncternal hits record low on plans to scrap studies, explore strategic alternatives;
Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Oncternal Therapeutics Q2 Net Income USD -8.559 Million
Oncternal Therapeutics Inc expected to post a loss of $3.10 a share - Earnings Preview
Brief: Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534
Brief: Oncternal Announces Enrollment Completed And Dosing Initiated For Fifth Dose Cohort Of Phase 1/2 Study Of Onct-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Oncternal Therapeutics Q1 Net Income USD -8.388 Million
Oncternal Therapeutics Inc expected to post a loss of $2.88 a share - Earnings Preview
Oncternal Therapeutics Inc expected to post a loss of $2.88 a share - Earnings Preview
Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Oncternal TherapeuticsOn Jan 22 Entered Into Amendment No. 4 To Amended & Restated License Agreement Between Co,Regents Of University Of California
Brief: Oncternal Therapeutics Updates The Status Of Its Phase 1/2 Study Of Onct-808
Brief: Oncternal Therapeutics Q3 Net Income USD -9.862 Million
Oncternal Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Oncternal Therapeutics -On Oct 3, Nasdaq Notified That It Has Granted Co Additional 180 Calendar Days To Regain Compliance With Minimum Bid Requirement